Novo Nordisk's stock has declined 67% from its 2024 peak, trading near $47 per share, yet the decline may present a compelling valuation opportunity for investors with extended time horizons. The Danish pharmaceutical company has solidified its market position in the obesity treatment sector with FDA-approved oral formulations of its flagship GLP-1 drugs Wegovy and Ozempic, addressing a significant market gap as demand for weight-loss medications continues to expand globally.
From a fundamental perspective, Novo Nordisk is trading at a price-to-free-cash-flow ratio below 23x, which sits beneath broader market averages. The company projects free cash flow growth of 17.5% going forward, while maintaining a dividend yield of 3.8%, providing both growth potential and current income. These metrics suggest the market may be pricing in execution risks more conservatively than historical precedent warrants.
Competitive pressures are materializing, with Eli Lilly expected to launch competing oral formulations in the second quarter of 2026. Nevertheless, Novo Nordisk's early-mover advantage in oral GLP-1 delivery, established manufacturing infrastructure, and substantial market share in the rapidly expanding obesity treatment category position it favorably for sustained revenue generation despite anticipated competition.